Download the ESMO 2012 Abstract Book - Oxford Journals

subject index
RCC, ix274 (830P)
re-staging PET-CT, ix237 (711P)
re-surgery, ix145 (416PD)
receptor tyrosine kinase inhibitor, ix319 (966O)
rechallenge, ix281 (849P)
RECIST, ix60 (112IN), ix487 (1506P), ix188
(554P), ix276 (834P)
rectal cancer, ix529 (1648P), ix208 (1704P), ix545
(1704P), ix197 (575P), ix206 (607P), ix206
(608P), ix207 (609P), ix207 (610P), ix207
(611P), ix208 (612P), ix208 (614P), ix211 (622),
ix215 (637), ix215 (638), ix222 (663TiP)
rectal cancers, ix184 (538P), ix193 (567P)
recurrence factor, ix132 (371P)
recurrence risk, ix179 (523PD)
recurrence, ix148 (426P), ix322 (977P)
recurrent cervical cancer, ix327 (995P)
recurrent ovarian cancer, ix323 (980P), ix324
(982P)
recurrent/metastatic salivary gland malignancies,
ix346 (1058)
recurrent, ix332 (1014), ix147 (424P)
reflex screening, ix176 (516P)
refractory Hodgkin’s lymphoma, ix350 (1071P)
refractory, ix492 (1519PD), ix286 (866P)
regorafenib, ix478 (1478O)
regulatory T-cells, ix75 (174O)
rehabilitation, ix513 (1592P)
reinforcement learning, ix459 (1411)
relapse, disease-free survival (DFS), ix356 (1091P)
relapse, ix227 (679P)
relapsed non-Hodgkin’s lymphoma, ix353 (1081P)
reliability, ix534 (1665P)
renal cancer, ix39 (51IN), ix39 (52IN), ix267
(808P)
renal cell cancer, ix274 (828P), ix281 (848P),
ix281 (850P), ix287 (869), ix288 (875), ix290
(880)
renal cell carcinoma (RCC), ix268 (811P), ix273
(827P), ix278 (840P), ix282 (853P), ix283
(856P)
renal cell carcinoma, ix453 (1390P), ix453
(1391P), ix454 (1392P), ix69 (153P), ix172
(501), ix39 (53IN), ix258 (784O), ix261
(792PD), ix262 (793PD), ix262 (794PD), ix262
(795PD), ix267 (809P), ix268 (812P), ix268
(813P), ix270 (817P), ix270 (818P), ix272
(823P), ix273 (825P), ix273 (826P), ix274
(829P), ix275 (832P), ix276 (834P), ix276
(836P), ix277 (838P), ix277 (839P), ix279
(844P), ix280 (846P), ix281 (847P), ix283
(855P), ix287 (872), ix288 (874), ix289 (876),
ix289 (877), ix289 (878), ix292 (889TiP)
renal function, ix171 (500P)
renal, ix267 (810P), ix269 (816P)
reproductive age, ix328 (998P)
research informatics, ix449 (1376P)
research, ix65 (135IN)
resectable gastroesophageal carcinoma, ix249
(753)
resectable locally-advanced, ix265 (802P)
resectable muscle-invasive, ix266 (807P)
resectable rectal cancer, ix216 (639)
resistance to treatment, ix287 (869)
resistance, ix390 (1197P), ix68 (148P), ix68
(149P), ix116 (318O), ix39 (52IN)
resource utilization, ix122 (336P)
response-shift, ix120 (331P)
response criteria, ix289 (877)
Response Evaluation Criteria in Solid Tumors
(RECIST), ix60 (111IN), ix535 (1670P), ix198
(579P)
response evaluation, ix483 (1492P)
response prediction, ix29 (19IN), ix37 (44IN)
response rate, ix389 (1191PD), ix415 (1267P),
ix496 (1534P)
response shift, ix109 (296P)
response to therapy, ix534 (1665P)
response to tyrosine kinase inhibitors, ix412
(1257P)
response, ix358 (1100)
retinoblastoma, ix149 (430P)
retroperitoneal lymph nodes, ix292 (888)
retrospective analysis, ix526 (1640)
retrospective study, ix370 (1136P), ix487 (1505P),
ix525 (1635), ix114 (313)
reverse-phase protein microarrays, ix536 (1674P)
review, ix49 (78IN)
RFA, ix35 (39IN)
rhabdomyosarcoma, ix484 (1497P)
rilotumumab, ix230 (687P)
risk factors, ix543 (1698P), ix134 (376), ix227
(679P), ix284 (859P)
risk, ix339 (1032P), ix364 (1119P), ix365 (1121P),
ix365 (1122P), ix133 (374P)
rituximab, ix351 (1074P), ix352 (1076P), ix352
(1079P), ix451 (1384P), ix70 (157P)
RNA sequencing, ix57 (100IN)
RNA, ix76 (177PD)
RO4929097, ix155 (448PD), ix156 (450PD)
RON, ix495 (1532P)
ROS1, ix389 (1191PD), ix81 (195P)
round robin panel testing, ix394 (1208)
Rrca1 mutant breast cancer mouse models, ix108
(290P)
RRM 1, ix67 (144PD)
S
S-1 plus cisplatin, ix404 (1234PD)
S-1 plus oxaliplatin, ix256 (779TiP), ix326 (989P)
s-1 plus paclitaxel, ix256 (779TiP)
S-1, ix385 (1181PD), ix436 (1334), ix193 (566P),
ix197 (576P), ix224 (668PD), ix225 (671P),
ix232 (695P), ix241 (728P), ix250 (758)
S1, ix217 (646)
safety and tolerability, ix403 (1231PD), ix163
(471P), ix240 (721P)
safety, cardio-toxicity, ix164 (476P)
safety, ix366 (1124P), ix402 (1230PD), ix419
(1277P), ix508 (1576P), ix516 (1604P), ix114
(315TiP), ix171 (499P), ix173 (507), ix224
(668PD), ix262 (795PD), ix308 (936P)
salivary duct carcinoma, ix344 (1706P)
salvage chemotherapy N, ix375 (1153)
salvage chemotherapy, ix63 (126IN), ix285 (860P)
sample size calculation, ix450 (1380P)
sarcoma, ix481 (1487P), ix482 (1488P), ix485
(1500P), ix485 (1501P), ix486 (1502P), ix486
(1504P), ix487 (1505P), ix489 (1514), ix490
(1517TiP), ix21 (1IN), ix166 (482P), ix54
(91IN), ix54 (92IN), ix55 (94IN)
satisfaction, ix511 (1584P)
SCCHN, ix334 (1018O)
schwannoma, ix150 (432)
SCLC, ix492 (1519PD), ix494 (1529P), ix498
(1543TiP)
screening process, ix53 (88IN)
screening tools, ix452 (1386P)
screening, ix456 (1402P), ix472 (1456P), ix252
(767)
second line therapy, ix438 (1342), ix497 (1540),
ix203 (597P), ix213 (632), ix242 (731P), ix265
(804P), ix277 (837P), ix314 (955)
second line, ix251 (761)
second-line chemotherapy, ix381 (1171P), ix429
(1306P), ix230 (688P), ix233 (697P)
second-line therapy, ix419 (1276P), ix232 (692P),
ix280 (846P)
second-line treatment, ix400 (1225O)
second-line, ix438 (1341)
secondary prophyalaxis, ix499 (1547PD)
secondary resection, ix190 (557P)
SEER-Medicare, ix205 (603P)
selective targeted drug, ix32 (29IN)
aelumetinib, ix403 (1233PD)
seminoma Stage 1, ix283 (857P)
Annals of Oncology
seminoma, ix284 (859P), ix286 (867P)
semuloparin, ix543 (1697P)
sensitive EGFR mutations, ix391 (1198P)
sensitivity analyses trabectedin progression-free
survival, ix324 (984P)
sentinel lymph node, ix112 (307)
sentinel node, ix106 (284P)
sequencing, ix38 (47IN)
sequential adjuvant chemotherapy, ix129 (360P)
sequential treatment, ix97 (253PD), ix272 (824P),
ix278 (840P), ix290 (881), ix314 (952), ix315
(958)
sequential, ix289 (876)
Serbian patients, ix428 (1304P)
serial evaluation, ix341 (1042P)
SERM, ix28 (17IN)
serous borderline tumor, ix322 (977P)
serous ovarian carcinoma, ix319 (969PD)
serum albumin levels, ix356 (1091P)
serum chromogranin-A, ix301 (912P)
serum HER2, ix136 (386)
serum tumor markers, ix80 (192P)
serum, ix78 (184P)
sex hormone binding globulin, ix304 (923P)
sex, ix455 (1396P)
sexual dysfunctions, ix474 (1463P)
sexuality, ix477 (1476)
shared, ix475 (1469P)
SHH, ix31 (25IN)
short chain fatty acid, ix200 (585P)
short-time infusion, ix203 (598P)
side-effects, ix518 (1610P), ix526 (1643)
signaling pathways, ix541 (1690P), ix40 (56IN)
signet ring cell, ix89 (225P), ix184 (541P), ix249
(753)
simultaneous resection, ix201 (589P)
simvastatin, ix72 (165)
single agent, ix398 (1220)
single institutional review, ix133 (373P)
single nucleotide polymorphism (SNP), ix434
(1326), ix528 (1646PD), ix85 (208P), ix92 (235),
ix209 (615), ix246 (742P)
sipuleucel-t, ix38 (46IN), ix310 (939P), ix310
(940P), ix310 (941P), ix311 (942P), ix311
(943P), ix313 (949)
siRNA (short-interfering RNA), ix536 (1673P)
skeletal–related events, ix447 (1372P), ix524
(1633)
skeletal-related event (SRE), ix360 (1108TiP),
ix449 (1377P)
skin toxicity, ix426 (1298P), ix435 (1328), ix514
(1597P), ix192 (563P)
skin-test infiltrating lymphocytes, ix363 (1114PD)
sleep difficulties, ix474 (1465P)
SMAD7, ix209 (615)
small bowel adenocarcinoma, ix234 (703P)
small breast cancer, ix111 (303)
small cell cancer, ix291 (886)
small cell lung cancer (SCLC), ix492 (1520PD),
ix493 (1525P), ix494 (1526P), ix494 (1527P),
ix497 (1540)
small cell lung cancer, ix493 (1523P), ix495
(1530P)
small molecule, ix32 (29IN)
small tumors, ix104 (276P)
smoking status, ix412 (1257P), ix420 (1280P),
ix455 (1396P), ix469 (1448PD)
SN-38, ix167 (485P)
SNPs, ix339 (1032P), ix243 (734P)
socio-econonomic status, ix165 (479P)
SOCS (suppressor of cytokine signaling), ix69
(153P)
sodium folinic acid (S-FA), ix185 (542P)
soft tissue sarcoma, ix483 (1493P), ix484 (1496P),
ix486 (1503P), ix487 (1506P), ix54 (91IN)
soft tissue sarcomas, ix485 (1498P), ix489 (1512)
solid and haematological malignancies, ix520
(1617), ix524 (1631)
ix598 | subject index Volume 23 | Supplement 9 | September 2012